标准化特异性免疫治疗儿童哮喘的不良反应观察

目的探讨标准化特异性免疫治疗(specific immunotherapy,SIT)儿童哮喘的不良反应。方法对673例儿童哮喘患者采用标准化屋尘螨过敏原制剂(安脱达)进行特异性免疫治疗21 860次,观察其不良反应。结果出现不良反应776例次(3.5%),种类有局部肿块、咳嗽、胸闷、眼鼻症状、皮疹、瘙痒、肺部哮鸣音、喉痒、发热等症状。各种不良反应发生率均低于3%(属于小概率事件);以局部反应较多而全身反应较少,无一例哮喘急性发作和过敏性休克发生;主要发生在维持治疗阶段。结论 SIT用于治疗过敏性哮喘是一种较安全的治疗措施。

Observation on adverse reactions of standardized specific immunotherapy in child asthma

Objective To investigate the adverse reactions of standardized specific immunotherapy（SIT） in child asthma.Methods 673 children cases of bronchial asthma received SIT with standardized house dust mite allergen preparation（Alutard SQ） for 21860 times.Results 776 case-times（3.5%） appeared adverse reactions including local mass,cough,chest tightness,symptoms of eyes and noses,rash,itching,wheezing,itching of throat and fever.The occurrence rate of various adverse reaction was less than 3 %（belonging to the small probability event）.The majority was local reactions with less systemic reactions.No case of asthma acute attack and anaphylactic shock ocurred.The adverse reactions occurred mostly in maintenance treatment period.Conclusion SIT is a safer treatment measure in treating allergic asthma.